StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
DFTXDefinium Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$35.72▲ 0.15%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.45BShares out 1.200M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

29
  • 9.30Overnight26.09.30 10:15
    4Ownership#●●●

    Definium Therapeutics, Inc.

    Insider Karlin Daniel of Definium Therapeutics, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more

    $35.72+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.30Overnight26.09.30 10:14
    4Ownership

    Definium Therapeutics, Inc.

    Insider Robert Barrow of Definium Therapeutics, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing serves as a formal disclosure of insider equity movement via Form 4.…more

    $35.72+0.15%vs prev close
    View filingShare
  • 9.30Overnight26.09.30 10:12
    4Ownership

    Definium Therapeutics, Inc.

    Definium Therapeutics, Inc. insider Matthew T. Wiley filed a Form 4 on September 29, 2026, reporting a change in beneficial ownership of securities as of September 25, 2026. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more

    $35.72+0.15%vs prev close
    View filingShare

28 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.14Regular26.09.15 00:13
    Bullish#●●●#●●●#●●●

    Definium Reports Successful Phase 3 Results for Anxiety Drug

    Definium's anxiety treatment DT120 met its primary endpoint in a Phase 3 study, demonstrating statistically significant symptom improvement compared to placebo. The company plans to move forward with an NDA submission following these positive clinical results.…more

    $35.72+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.14Pre-market26.09.14 20:25

    ●●●●●●●● ●●●●● ●●●●●●

    The trading halt for Definium Therapeutics (DFTX) has been lifted and trading has resumed. Information regarding the halt status and the resumption time has been updated.…more

    $35.72+0.15%vs prev close
    ShareBenzinga
  • 9.14Pre-market26.09.14 20:03

    ●●●●●●●● ●●●●● ●●●●●●

    Definium Therapeutics reported that its Phase 3 Panorama study for DT120 in generalized anxiety disorder met all primary and key secondary efficacy endpoints. The company plans to proceed with a pre-NDA meeting in late 2026 and expects to file for regulatory approval in the first half of 2027.…more

    $35.72+0.15%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →